These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23211054)

  • 1. Premotor biomarkers for Parkinson's disease - a promising direction of research.
    Haas BR; Stewart TH; Zhang J
    Transl Neurodegener; 2012 May; 1(1):11. PubMed ID: 23211054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for cognitive impairment in Parkinson disease.
    Shi M; Huber BR; Zhang J
    Brain Pathol; 2010 May; 20(3):660-71. PubMed ID: 20522092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson's Disease.
    Xie F; Gao X; Yang W; Chang Z; Yang X; Wei X; Huang Z; Xie H; Yue Z; Zhou F; Wang Q
    ACS Chem Neurosci; 2019 Feb; 10(2):973-990. PubMed ID: 30590011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging candidate biomarkers for Parkinson's disease: a review.
    Saracchi E; Fermi S; Brighina L
    Aging Dis; 2014 Feb; 5(1):27-34. PubMed ID: 24490114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Biomarkers for Parkinson's Disease.
    He R; Yan X; Guo J; Xu Q; Tang B; Sun Q
    Front Aging Neurosci; 2018; 10():305. PubMed ID: 30364199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.
    Ren R; Sun Y; Zhao X; Pu X
    Clin Chem Lab Med; 2015 Sep; 53(10):1495-506. PubMed ID: 25581757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease.
    Yokoi K; Hattori M; Satake Y; Tanaka Y; Sato M; Hashizume A; Hori A; Kawashima M; Hirakawa A; Watanabe H; Katsuno M
    Sci Rep; 2020 Nov; 10(1):20524. PubMed ID: 33239649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in defining the premotor phase of Parkinson's disease.
    Tolosa E; Pont-Sunyer C
    J Neurol Sci; 2011 Nov; 310(1-2):4-8. PubMed ID: 21679972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.
    Lee SH; Park SM; Yeo SS; Kwon O; Lee MK; Yoo H; Ahn EK; Jang JY; Jang JH
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New markers in Parkinson's disease.
    Bougea A
    Adv Clin Chem; 2020; 96():137-178. PubMed ID: 32362317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.
    Andersen AD; Binzer M; Stenager E; Gramsbergen JB
    Acta Neurol Scand; 2017 Jan; 135(1):34-56. PubMed ID: 26991855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing Premotor Parkinson's Disease: Clinical Features and Objective Markers.
    Chahine LM; Stern MB
    Mov Disord Clin Pract; 2014 Dec; 1(4):299-306. PubMed ID: 30363867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
    Loeffler DA; Aasly JO; LeWitt PA; Coffey MP
    J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
    Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
    Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study.
    Liepelt-Scarfone I; Gauss K; Maetzler W; Müller K; Bormann C; Fruhmann Berger M; Timmers M; Streffer J; Berg D
    Neuroepidemiology; 2013; 41(3-4):174-82. PubMed ID: 24051361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.